ABSTRACT
For an emergent disease, such as Covid-19, with no past epidemiological data to guide models, modelers struggle to make predictions of the course of the epidemic (Cyranoski, Nature News 18 February 2020). The wildly varying predictions make it difficult to base policy decisions on. On the other hand much empirical information is already contained in data of evolving epidemiological profiles. We offer an additional tool, based on general theoretical principles and validated with data, for tracking the turning points, peak and accumulated case numbers of infected and recovered for an epidemic, and to predict its course. Ability to predict the turning points and the epidemic’s end is of crucial importance for fighting the epidemic and planning for a return to normalcy. The accuracy of the prediction of the peaks of the epidemic is validated using data in different regions in China showing the effects of different levels of quarantine. The validated tool can be applied to other countries where Covid-19 has spread, and generally to future epidemics. US is found to have the largest net infection rate, and is predicted to have the largest total infected cases (708K) and will take two weeks longer than Wuhan to reach its turning point, and one week longer than Italy and Germany.
SIGNIFICANCE We offer a practical tool for tracking and predicting the course of an epidemic using the daily data on the infection and recovery. This data-driven tool can predict the turning points two weeks in advance, with an accuracy of 2-3 days, validated using data from various regions in China selected to show the effects of quarantine. It also gives information on how rapid the rise and fall of the case numbers are, and what the peak and total number of infected are. Although empirical, this approach has a sound theoretical foundation; the main components of the results are validated after the epidemic is near an end, as is the case for China, and therefore is generally applicable to future epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding information.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are publicly available.
